Loading clinical trials...

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial | Clinical Trials | Clareo Health

RECRUITINGNA

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

NCT07103382•Second Xiangya Hospital of Central South University

View on ClinicalTrials.gov

Summary

To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Obese individuals:
•Aged 18-60 years, regardless of sex/gender
•BMI≥28.0kg/m2
•Overweight or obese individuals with type 2 diabetes:
•Aged 18-60 years, regardless of sex/gender
•BMI≥24.0kg/m2
•HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol/l and ≤ 13.3 mmol/l at screening
•Stable diabetes treatment for at least 6 months or more

Exclusion Criteria

•Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes
•Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections
•Use of weight-affecting products within the past three months or planned use during the study
•Weight fluctuation \>5 kg or \>10% within the past three months
•Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome)
•Uncontrolled hypertension, severe cardiac/hepatic/renal dysfunction
•History of gastrointestinal surgery (such as cholecystectomy) within the past year or non-gastrointestinal surgery within six months, or prior bariatric surgery
•Chronic gastrointestinal disorders (such as recurrent constipation, celiac disease, or food intolerances) or any condition impairing digestion/absorption function
•History of malignant tumors within five years, regardless of whether there is recurrence or metastasis and severe immune dysfunction (such as malignant tumors, HIV/AIDS, immunodeficiency diseases)
•Use of probiotics, prebiotics, or antibiotics within three months prior to enrollment, or alcohol abuse; Consumption of yogurt within two weeks before the study or during the trial period; History of psychiatric or infectious diseases
+3 more criteria

Locations (1)

Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University

Changsha, Hunan, China

Key Dates

Start Date

June 26, 2025

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

September 5, 2025

Enrollment

ESTIMATED participants

Conditions

Obesity

Interventions

Attapulgite

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Protein Supplementation Intervention on Body Weight

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss